#United States #Salt Lake City #Maternal Autoantibody #Autism Test #MARAbio Systems

MARAbio Launches Groundbreaking Blood Test for Autism

In a remarkable advancement for autism diagnosis, MARAbio Systems has launched the MAR-Autism Test, marking the first-ever blood test capable of identifying specific maternal autoantibodies that contribute to a particular type of autism known as Maternal Autoantibody Related Autism (MARA). This test has been developed following over 20 years of dedicated research at the UC Davis MIND Institute, led by founder and Chief Scientific Advisor, Dr. Judy Van de Water.

MARA is recognized as one of the more prevalent subtypes of autism, with research suggesting that it could affect as many as 1 in 5 individuals diagnosed with autism. The causative factor behind MARA involves maternal autoantibodies that traverse the placenta, thereby interfering with the healthy development of the child’s brain, which can lead to various neurodevelopmental disorders and autistic behaviors.

Clinical Validation and Specificity

The MAR-Autism Test has shown impressive clinical validation, demonstrating a specificity exceeding 99%. This robust accuracy ensures that the likelihood of false-positive results is exceedingly low. In clinical analyses, specific patterns of autoantibodies have been found to correspond to a 99% risk of diagnosing autism in children, providing a substantial tool for early detection.

Healthcare professionals across the United States can now order the MAR-Autism Test for mothers who have previously had a child diagnosed with autism. This test not only aims to assist families in understanding the potential future risks for younger siblings, but it is also available for mothers whose children are currently presenting autistic symptoms. The test is not validated for use during pregnancy and is primarily aimed at early detection and referrals for therapeutic interventions.

Significance of the Launch

Dr. Michael Paul, President and CEO of MARAbio, expressed the significance of this launch: "The introduction of the MAR-Autism blood test is a transformative advancement in autism detection, enhancing the likelihood of identifying autism in future generations." He emphasized that the pioneering research conducted by Dr. Van de Water and her team has enabled countless families and healthcare providers to explore a scientifically substantiated biological link to autism.

Dr. Van de Water shared her insight on the societal relevance of this development: "With a growing focus on autism and the demand to uncover its root causes, our work has gained notable attention. MARAbio was founded to provide scientific clarity and reassurance to mothers and families while aiming for the best possible outcomes for their children."

Autism researcher and clinician, Dr. Richard E. Frye, underscored the potential implications for families, saying, "With the availability of MARAbio’s test, particularly for families already affected by autism, we can gain significant insights into this highly prevalent cause, thus enhancing compassionate healthcare measures."

Future Directions

In tandem with the commercialization of the MAR-Autism Test, MARAbio is actively assessing therapeutic approaches to prevent fetal exposure to these harmful maternal autoantibodies, aiming to reduce the incidence of MARA worldwide. The mission of MARAbio is clear: to discover, address, and avert the challenges linked to Maternal Autoantibody Related Autism.

The MAR-Autism Test can be ordered through healthcare providers for eligible individuals. For detailed information regarding the test and instructions for healthcare professionals, prospective users can visit marautism.com.

About MARAbio

MARAbio Systems, Inc. (MARAbio) is a leading precision immunology company specializing in the detection of a distinct cluster of autoantibodies associated with Maternal Autoantibody Related Autism (MARA). The company’s flagship diagnostic product, the MAR-Autism Test, enables the prediction of the likelihood of MARA in children through a straightforward maternal blood test, even before the emergence of clinical symptoms. With a commitment to ensuring that families have access to this advanced form of testing, MARAbio continues to work towards enhancing awareness and expanding its accessibility amid ongoing research initiatives.